InvestorsHub Logo
Followers 0
Posts 601
Boards Moderated 0
Alias Born 01/23/2011

Re: Rooster8989 post# 1139

Friday, 05/12/2017 4:39:33 PM

Friday, May 12, 2017 4:39:33 PM

Post# of 9828
I missed this the 1st time around in your post... this must be old "about" data. Phase 2 hasn't started yet as far as I know... as of May 2017. Or am I missing something?

Original copy from your message:
OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVaxâ„¢ is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent THER News